Bio-Rad vs. Charles River Labs: Which Medical Research Stock Is a Better Buy in 2026?

Bio-Rad reported FY2025 revenue of nearly $2.6B and net income of about $759.9M, while Charles River reported just over $4.0B of revenue and a $144.3M net loss. The article favors Charles River for 2026 on valuation and restructuring progress, with FY2026 net income projected to rebound to $285M versus Bio-Rad's expected $225M. The piece is primarily comparative analysis and stock-picking commentary rather than a catalyst-driven update.

Analysis

CRL looks like the cleaner 2026 re-rating story because the market can underwrite a visible earnings inflection before the revenue base fully recovers. The important second-order effect is that management’s restructuring and supplier de-risking should improve margins even if top-line growth stays muted, which makes earnings revisions more likely to matter than absolute sales trends over the next 2-3 quarters. BIO has better balance-sheet optics, but the market is already paying for that resilience, so the path to outperformance requires a sharper-than-expected rebound in research funding or diagnostics demand.

The bigger competitive implication is that CRL’s weakness is partly industry-wide, but its client concentration is low enough that it can capture share if smaller research-service vendors are forced to retrench. A return to profitability next year also gives CRL more flexibility to defend share with pricing, selective M&A, or continued vertical integration, while weaker peers like LH face a more difficult mix of reimbursement pressure and slower CRO demand. By contrast, BIO’s exposure to international FX and policy-sensitive end markets means the downside is more about delayed growth than a true balance-sheet event.

The contrarian view is that the cheaper stock is not necessarily the better stock if the end-market turns are still being discounted too early. CRL’s recovery depends on execution in cost-out and supply-chain control, both of which are usually lagged benefits that can take 2-4 quarters to show up in reported margins. If the market starts pricing in a slower macro rebound or renewed biopharma capex cuts, the valuation gap can close by multiple compression on CRL rather than upside on BIO, so the better trade is to own the turnaround with a defined risk horizon rather than chase an outright long.

Key Decisions for Investors

• Go long CRL over BIO.B on a 6-12 month horizon; the setup favors earnings revision upside and multiple expansion if profitability inflects as expected.
• Use a pair trade: long CRL / short LH for the next 2-3 quarters to express relative recovery in outsourced discovery services versus a more challenged services platform.
• Avoid outright BIO.B longs unless there is evidence of faster-than-expected funding stabilization; the stock is more of a quality hold than a near-term catalyst trade.
• For higher-conviction expression, buy CRL call spreads 6-9 months out to capture the rerating while limiting downside if restructuring savings slip by a quarter.
• Set a stop on CRL if management commentary suggests the 2026 profitability swing is being deferred; the trade works only if cost savings and supply-chain actions show up in forward guidance.